p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment.
Animals-Newborn, Brain, Cyclin-Dependent-Kinases, Enzyme-Activation, Fetal-Viability, Gene-Dosage, Gene-Targeting, Genes-Lethal, Homozygote, Macromolecular-Systems, Mice, Mice-Neurologic-Mutants, Motor-Neurons, Nerve-Tissue-Proteins, Nervous-System-Malformations, Phenotype, Phosphorylation, Transplantation-Chimera
J Neurosci 2001 Sep; 21(17):6758-71.
Cyclin-dependent kinase 5 (Cdk5) plays a pivotal role in brain development and neuronal migration. Cdk5 is abundant in postmitotic, terminally differentiated neurons. The ability of Cdk5 to phosphorylate substrates is dependent on activation by its neuronal-specific activators p35 and p39. There exist striking differences in the phenotypic severity of Cdk5-deficient mice and p35-deficient mice. Cdk5-null mutants show a more severe disruption of lamination in the cerebral cortex, hippocampus, and cerebellum. In addition, Cdk5-null mice display perinatal lethality, whereas p35-null mice are viable. These discrepancies have been attributed to the function of other Cdk5 activators, such as p39. To understand the roles of p39 and p35, we created p39-null mice and p35/p39 compound-mutant mice. Interestingly, p39-null mice show no obvious detectable abnormalities, whereas p35(-/-)p39(-/-) double-null mutants are perinatal lethal. We show here that the p35(-/-)p39(-/-) mutants exhibit phenotypes identical to those of the Cdk5-null mutant mice. Other compound-mutant mice with intermediate phenotypes allow us to determine the distinct and redundant functions between p35 and p39. Our data strongly suggest that p35 and p39 are essential for Cdk5 activity during the development of the nervous system. Thus, p35 and p39 are likely to be the principal, if not the only, activators of Cdk5.
Ko, J; Humbert, S; Bronson, R T.; Takahashi, S; Kulkarni, A B.; Li, E; and Tsai, L H., " p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment." (2001). Faculty Research 2000 - 2009. 231.